Todos We are happy to achieve this important mile
Post# of 30067
(Total Views: 516)
Posted On: 05/28/2019 10:15:43 PM
Todos
We are happy to achieve this important milestone approval from the Ministry of Health of the State of Israel. This approval, along with our recent signing of a distribution agreement for our cancer screens with Care GB in Israel, enables us to move forward at full strength to commercialize our products,” said Dr. Herman Weiss, CEO of Todos Medical. “We are now actively working to begin sales in Austria, Romania and Israel.”
http://investor.todosmedical.com/news-release...ealth-amar
Todos
On April 29, 2019, the Company held its Annual General Meeting of Shareholders, at which the shareholders of the Company approved the following proposals:
(1) The approval of a reverse share split of the Company’s ordinary shares within a range of 10:1 to 150:1, to be effective at the ratio and on a date to be determined by the Board of Directors of the Company, and to amend the Articles of Association of the Company accordingly;
"We are in the process of applying to list our ordinary shares on The Nasdaq Capital Market under the symbol “ ”...."
We recently raised $1,215,450 from the sale of convertible notes, which have an outstanding principal balance of $1,350,500. On February 27, 2019, we entered into a convertible bridge loan agreement, and have issued notes and warrants relating thereto, to obtain aggregate loans in the principal amount of $1,350,500 from several private lenders, including DPH Investment Ltd., a holder of 11.5% of our shares (as of such date), to finance the Company’s activities through the consummation of a proposed public offering and our planned uplisting to the NASDAQ Capital Market. As of April 15, 2019, we have obtained $1,010,500 in bridge loan financing, and we have commitments for an additional $340,000 linked to certain milestones.
http://investor.todosmedical.com/node/6616/html
There are other options on the table for bringing in cash this year.
Owning 50% (49.99%) of a company that raises capital to uplist on the NASDAQ and have a DX that is generating revenue along with a possible REG A+ shows a possible path for war and that is not including
MANF Therapeutics
Cutanogen Corp.
And what they are doing with Coeptis Pharma.
Looking forward to what Gerald will be providing as a full company update.
Aloha
We are happy to achieve this important milestone approval from the Ministry of Health of the State of Israel. This approval, along with our recent signing of a distribution agreement for our cancer screens with Care GB in Israel, enables us to move forward at full strength to commercialize our products,” said Dr. Herman Weiss, CEO of Todos Medical. “We are now actively working to begin sales in Austria, Romania and Israel.”
http://investor.todosmedical.com/news-release...ealth-amar
Todos
On April 29, 2019, the Company held its Annual General Meeting of Shareholders, at which the shareholders of the Company approved the following proposals:
(1) The approval of a reverse share split of the Company’s ordinary shares within a range of 10:1 to 150:1, to be effective at the ratio and on a date to be determined by the Board of Directors of the Company, and to amend the Articles of Association of the Company accordingly;
"We are in the process of applying to list our ordinary shares on The Nasdaq Capital Market under the symbol “ ”...."
We recently raised $1,215,450 from the sale of convertible notes, which have an outstanding principal balance of $1,350,500. On February 27, 2019, we entered into a convertible bridge loan agreement, and have issued notes and warrants relating thereto, to obtain aggregate loans in the principal amount of $1,350,500 from several private lenders, including DPH Investment Ltd., a holder of 11.5% of our shares (as of such date), to finance the Company’s activities through the consummation of a proposed public offering and our planned uplisting to the NASDAQ Capital Market. As of April 15, 2019, we have obtained $1,010,500 in bridge loan financing, and we have commitments for an additional $340,000 linked to certain milestones.
http://investor.todosmedical.com/node/6616/html
There are other options on the table for bringing in cash this year.
Owning 50% (49.99%) of a company that raises capital to uplist on the NASDAQ and have a DX that is generating revenue along with a possible REG A+ shows a possible path for war and that is not including
MANF Therapeutics
Cutanogen Corp.
And what they are doing with Coeptis Pharma.
Looking forward to what Gerald will be providing as a full company update.
Aloha
(2)
(0)